亚宝药业：关于研发项目终止临床试验并计提减值准备的公告

Core Viewpoint - The company has decided to terminate the clinical research and development of the SY-009 project after a careful evaluation of its progress, investment risks, and future market value [2] Group 1 - The decision to halt the SY-009 project is aimed at rationally allocating the company's research and development resources [2] - The company will fully recognize the impairment of the capitalized amount related to the SY-009 project based on accounting prudence principles [2] - The focus will now shift to the company's advantageous projects within its research pipeline [2]